Standout Papers

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced ... 2017 2026 2020 2023 332
  1. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial (2017)
    Beatrice Seddon, Sandra J. Strauss et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 62 standout
Sub-graph 1 of 22

Citing Papers

Nationwide real-world implementation of AI for cancer detection in population-based mammography screening
2025 Standout
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
2024 Standout
2 intermediate papers

Works of Sharon Forsyth being referenced

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
2010

Author Peers

Author Last Decade Papers Cites
Sharon Forsyth 552 420 190 384 26 967
Caroline Seynaeve 560 351 219 372 24 1.1k
Jean‐Pierre Ghnassia 456 365 115 251 27 821
A. Avril 588 254 240 720 35 1.1k
Reginald P. Pugh 578 269 116 219 34 1.1k
Isabelle Neyroud‐Caspar 709 251 144 618 18 1.1k
Ana M. Gonzalez‐Angulo 691 285 138 519 22 1.1k
J. G. Ribot 446 217 497 231 20 1.1k
L. Kayitalire 733 443 169 159 40 1.1k
Heidi Stranzl 499 210 258 522 29 1.0k
K.I. Pritchard 672 180 145 572 34 1.1k

All Works

Loading papers...

Rankless by CCL
2026